Drug Type Small molecule drug |
Synonyms Nimoral, Nimorazole (INN), K-1900 + [3] |
Target- |
Mechanism DNA synthesis inhibitors |
Active Indication |
Inactive Indication |
Originator Organization- |
Active Organization- |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date- |
RegulationOrphan Drug (EU) |
Molecular FormulaC9H14N4O3 |
InChIKeyMDJFHRLTPRPZLY-UHFFFAOYSA-N |
CAS Registry6506-37-2 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D07352 | Nimorazole |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Amebiasis | - | - | - |
Giardiasis | - | - | - |
Gingivitis | - | - | - |
Trichomonas Infections | - | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Locally Advanced Head and Neck Squamous Cell Carcinoma | Phase 3 | GB | 11 Sep 2014 |
Phase 3 | 139 | Nimorazole+RT (hypoxic group) | nuoyfwijsx(woncziktov): adjusted HR = 0.72 (95% CI, 0.36 - 1.44), P-Value = 0.35 View more | Negative | 31 May 2023 | ||
Placebo+RT (hypoxic group) |